📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 15:55
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
Vaishali Pharma Approves Q1 FY27 Results; 19th AGM Scheduled for Sept 24, 2026
Vaishali Pharma's board approved the unaudited financial results for the first quarter ended June 30, 2026, during its meeting on August 14, 2026. The company also finalized the 19th Annual General Meeting (AGM) for September 24, 2026, and set the book closure period from September 18 to September 24. This follows a fiscal year (FY26) where the company reported a revenue of Rs 85.03 Cr and a net profit of Rs 2.92 Cr. Investors are monitoring the company's strategic shift from low-margin API trading to high-margin formulations to improve its 3.23% operating margin.
Confidence: HIGH
What changedThe board has officially approved the first-quarter performance figures for FY27 and established the timeline for the annual shareholder meeting and book closure.
Why it mattersThis filing initiates the formal reporting cycle for the new fiscal year and provides the necessary schedule for shareholders to participate in the upcoming AGM.
AGM Date: 24th September, 2026Book Closure Start: 18th September, 2026FY26 Revenue: Rs 85.03 CrFY26 Net Profit: Rs 2.92 CrPromoter Holding: 30.54%
📅 Short termThe stock may see minor activity as investors digest the Q1 FY27 earnings performance relative to previous quarters.
📈 Long termThe long-term outlook depends on the company's ability to successfully transition from a thin-margin API trader to a higher-margin formulation and veterinary product player.
⚠ Risk flags
- Thin operating margins (3.23% in FY26)
- High revenue dependency (60%) on volatile API trading prices
- Relatively low promoter holding at 30.54%
Key Highlights
Board approved Q1 FY27 unaudited financial results on August 14, 2026.
19th Annual General Meeting (AGM) scheduled for September 24, 2026, via video conferencing.
Book closure period for the AGM set from September 18 to September 24, 2026.
Company reported FY26 annual revenue of Rs 85.03 Cr with a net profit of Rs 2.92 Cr.
Strategic goal remains reaching Rs 500 Cr revenue in 5 years by increasing formulation share to 50%.
👀 What to Watch
Investors should examine the Q1 FY27 results to verify if the operating margin is expanding beyond the FY26 level of 3.23% as the company pivots toward branded formulations.
45.37 Lakh shares allotted to Kesar Pharma for 26.95% stake acquisition
Vaishali Pharma has completed the allotment of 45,37,865 equity shares at an issue price of Rs 20 per share to Kesar Pharma Limited (KPL). This is a non-cash transaction valued at Rs 9.08 Cr, executed as a share swap to acquire a 26.95% stake in KPL. The allotment increases Vaishali's total paid-up equity shares to 13.50 Cr, with KPL now holding a 3.36% stake in the company. This move aligns with the company's strategy to expand its pharmaceutical footprint through strategic investments.
Confidence: HIGH
What changedVaishali Pharma has issued new equity shares to Kesar Pharma Limited as consideration for acquiring a 26.95% stake in the latter.
Why it mattersThis strategic investment allows Vaishali to expand its pharmaceutical interests without cash outflow, though it results in a 3.36% equity dilution for existing shareholders.
Total Allotment Value: Rs 9.08 CrStake Acquired in KPL: 26.95%Issue Price per Share: Rs 20Transaction vs Net Worth: 13.16%Post-Issue Total Shares: 13,49,99,995
📅 Short termThe market is likely to view the completion of this long-pending acquisition (initiated in Feb 2026) as a positive step toward inorganic growth.
📈 Long termThe acquisition of a significant minority stake in KPL could provide synergies in the formulation and API segments, supporting the company's margin expansion goals.
⚠ Risk flags
- Equity dilution of 3.36%
- Valuation risk of the acquired stake in a non-listed entity
- Integration and synergy realization risks
Key Highlights
Allotment of 45,37,865 equity shares at Rs 20 per share (including Rs 18 premium)
Acquisition of 26.95% stake in Kesar Pharma Limited via share swap
Total transaction value of Rs 9.08 Cr, representing approximately 13.1% of Vaishali's net worth
Paid-up equity capital increased from Rs 26.09 Cr to Rs 27.00 Cr
Kesar Pharma Limited now holds a 3.36% post-preferential stake in Vaishali Pharma
👀 What to Watch
Investors should monitor the financial performance of Kesar Pharma Limited as an associate company and observe how this acquisition aids Vaishali's target of reaching Rs 500 Cr revenue in 5 years.
4.54M shares allotted to Kesar Pharma for 26.95% stake acquisition via share swap
Vaishali Pharma has completed the allotment of 4,537,865 equity shares at Rs. 20 per share to Kesar Pharma Limited (KPL). This is a non-cash transaction valued at Rs. 9.08 crore, executed as a share swap to acquire a 26.95% stake in KPL. The move aligns with the company's stated strategy to shift its revenue mix toward high-margin formulations. Post-allotment, KPL holds a 3.36% stake in Vaishali Pharma, and the total paid-up shares have increased to 13.49 crore.
Confidence: HIGH
What changedVaishali Pharma has finalized a strategic investment in Kesar Pharma Ltd by issuing new equity shares as payment for a 26.95% stake.
Why it mattersThis acquisition is a step toward the company's goal of reaching Rs. 500 Cr revenue by shifting from API trading to high-margin formulations, potentially securing manufacturing synergies.
Total Allotment Value: Rs. 9.08 CrStake Acquired in KPL: 26.95%Issue Price per Share: Rs. 20Transaction vs Net Worth: ~13.1%Equity Dilution: 3.48%
📅 Short termThe market is likely to view the strategic acquisition positively, though the immediate impact may be tempered by the 3.48% equity dilution.
📈 Long termIf Kesar Pharma provides critical manufacturing support, it could help Vaishali achieve its target of a 50/50 API-formulation revenue split and improved ROCE.
⚠ Risk flags
- Minority stake (26.95%) limits direct control over Kesar Pharma operations
- Equity dilution for existing shareholders
Key Highlights
Allotment of 4,537,865 equity shares at an issue price of Rs. 20 per share
Acquisition of a 26.95% stake in Kesar Pharma Limited for a total consideration of Rs. 9.08 crore
Paid-up equity share capital increased from 13.04 crore shares to 13.49 crore shares
Kesar Pharma Limited now holds a 3.36% post-issue stake in Vaishali Pharma
Transaction executed as a share swap (consideration other than cash)
👀 What to Watch
Investors should monitor the operational integration of Kesar Pharma and how this minority stake contributes to Vaishali's goal of increasing formulation margins from 16% to 25%.
Vaishali Pharma to Receive Rs 2.15 Lakh Cash from KPL to Align Share Swap Valuation
Vaishali Pharma Limited is addressing a valuation discrepancy regarding its preferential issue of 61,23,000 equity shares to Kesar Pharma Limited (KPL). The company originally valued KPL shares at Rs 56.89 for the swap, but the registered valuer's report cited Rs 56.79, a difference of Rs 0.10 per share. To satisfy NSE's observations for in-principle approval, KPL will pay the aggregate differential of Rs 2,15,258 in cash to Vaishali Pharma. This adjustment ensures the transaction aligns perfectly with the valuation report and regulatory requirements.
Key Highlights
Preferential issuance of up to 61,23,000 equity shares to Kesar Pharma Limited (KPL) via share swap.
Acquisition involves 21,52,575 equity shares of KPL.
Valuation discrepancy of Rs 0.10 per share identified between company calculation and valuer report.
KPL to pay Rs 2,15,258 in cash to bridge the valuation gap for regulatory compliance.
Adjustment made specifically to address National Stock Exchange (NSE) observations for in-principle approval.
👀 What to Watch
Investors should view this as a routine regulatory correction that clears the path for the completion of the preferential issue. Monitor for the final in-principle approval from the NSE to confirm the transaction's progress.
Vaishali Pharma Proposes Re-appointment of MD and WTD, and CFO Remuneration Hike
Vaishali Pharma Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of its core leadership team for five-year terms. This includes Managing Director Atul Arvind Vasani and Whole-Time Director Jagruti Vasani, both for terms ending in May 2031. Additionally, the company is proposing a second five-year term for Independent Director Pratik Vikram Jakhelia and an increase in remuneration for CFO Dewansh Ajay Vasani. The voting process will be conducted electronically between June 4 and July 3, 2026.
Key Highlights
Proposed 5-year re-appointment of Managing Director Atul Arvind Vasani effective from May 23, 2026.
Proposed 5-year re-appointment of Whole-Time Director Jagruti Vasani effective from May 23, 2026.
Resolution to increase the remuneration payable to Dewansh Ajay Vasani, Director and CFO.
Re-appointment of Pratik Vikram Jakhelia as Independent Director for a second term until September 30, 2031.
E-voting period scheduled from June 4, 2026, to July 3, 2026, with results by July 7, 2026.
👀 What to Watch
Investors should monitor the voting results to ensure leadership continuity and review the explanatory statement to assess if the CFO's remuneration hike is justified by company performance.
Vaishali Pharma Approves Audited Q4 and FY26 Financial Results
The Board of Directors of Vaishali Pharma Limited met on May 30, 2026, to approve the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The meeting was held late in the evening, concluding at 10:50 P.M. This announcement confirms the completion of the annual audit process in compliance with SEBI regulations. While specific financial figures were not detailed in the cover letter, the approval marks the formal release of the company's performance data for the 2025-26 fiscal year.
Key Highlights
Board approved Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026.
The meeting was conducted on May 30, 2026, starting at 10:00 P.M. and ending at 10:50 P.M.
The submission includes the Audit Report for both the fourth quarter and the full financial year.
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 What to Watch
Investors should review the detailed financial tables in the attached Annexure I to assess revenue growth and margin stability. Compare the full-year FY26 performance against FY25 to determine the company's growth trajectory.
Vaishali Pharma Re-appoints MD Atul Vasani and Two Directors for 5-Year Terms
Vaishali Pharma Limited has announced the re-appointment of its core leadership team for five-year terms during its board meeting on May 23, 2026. Mr. Atul Arvind Vasani, the promoter and chairman with over 30 years of industry experience, has been re-appointed as Managing Director until May 2031. Mrs. Jagruti Vasani continues as Whole-Time Director, while Mr. Pratik Vikram Jakhelia has been re-appointed as an Independent Director for a second term. These leadership extensions, subject to shareholder approval, ensure management continuity and stability for the company's long-term operations.
Key Highlights
Mr. Atul Arvind Vasani re-appointed as Managing Director for a 5-year term ending May 22, 2031
Mrs. Jagruti Vasani re-appointed as Whole-Time Director for 5 years, bringing 15+ years of experience
Mr. Pratik Vikram Jakhelia re-appointed as Independent Director for a 2nd term of 5 years starting Sept 2026
The leadership team includes the promoter who has been in the pharmaceutical industry since 1987
All re-appointments are subject to the final approval of the company's members
👀 What to Watch
This announcement confirms management continuity, which is a positive sign for long-term stability. Investors should monitor the company's performance under this established leadership.
Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares
Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.
Key Highlights
Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.
The resolution received 99.9909% votes in favor from the public non-institutional category.
A total of 25,415,321 votes were polled during the postal ballot process.
Promoters and promoter group members abstained from voting due to their interest in the resolution.
The record date for determining eligibility for the postal ballot was February 6, 2026.
👀 What to Watch
Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
Key Highlights
Proposed acquisition of a 51.02% majority stake in Kesar Pharma Limited
Preferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46
Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02
Relevant date for the transaction pricing is February 13, 2026
E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
👀 What to Watch
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
Key Highlights
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per share
Total consideration of Rs. 12.25 crores to be settled via share swap (non-cash)
Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stake
Relevant date for floor price determination fixed as February 13, 2026
E-voting results to be announced on or before March 17, 2026
👀 What to Watch
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
Vaishali Pharma Approves Rs 12.25 Cr Share Swap for Kesar Pharma Stake
Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.
Key Highlights
Issuance of 61,23,000 equity shares at a price of Rs 20 per share
Total deal value of Rs 12.246 Crores via share swap for Kesar Pharma stake
Acquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per share
Post-allotment, Kesar Pharma Limited will own 4.48% of Vaishali Pharma
Board approved Q3 FY26 results and initiated a postal ballot for shareholder approval
👀 What to Watch
Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.
Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake
Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.
Key Highlights
Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).
Total transaction value for the share swap is ₹12,24,60,000.
Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.
Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.
Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.
👀 What to Watch
Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.
Vaishali Pharma to Issue Shares Worth ₹12.25 Cr via Swap for Kesar Pharma Stake
Vaishali Pharma's board has approved a preferential allotment of 61.23 lakh equity shares at ₹20 per share, totaling ₹12.25 crore. This is a non-cash transaction executed via a share swap to acquire 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. The board also cleared the unaudited financial results for the quarter ended December 31, 2025. This move will result in Kesar Pharma Limited holding a 4.48% stake in Vaishali Pharma post-allotment.
Key Highlights
Issuance of 61,23,000 equity shares at ₹20 per share aggregating to ₹12.246 Crores.
Transaction involves a share swap for 21,52,575 shares of associate company Kesar Pharma.
Kesar Pharma Limited to hold 4.48% post-issue equity in Vaishali Pharma.
Board approved Q3 and 9M FY26 financial results during the same meeting.
Relevant date for floor price determination set as February 13, 2026.
👀 What to Watch
Investors should review the Q3 financial performance and assess the strategic value of increasing the stake in Kesar Pharma. Monitor the upcoming postal ballot results for shareholder approval of this preferential issue.
Vaishali Pharma: 2,32,70,000 Equity Shares Listed on NSE
Vaishali Pharma Limited received approval from NSE for trading of 2,32,70,000 equity shares of ₹2 each. These shares, bearing distinctive numbers from 107192131 to 130462130, were issued to Promoters and Non-Promoters on a preferential basis following the conversion of warrants. The equity shares were listed and admitted to dealings on the Exchange effective December 09, 2025. Investors should note the lock-in periods for specific share ranges as detailed in Annexure I.
Key Highlights
2,32,70,000 equity shares of ₹2 each listed on NSE
Shares issued to Promoters and Non-Promoters on preferential basis
Distinctive numbers range from 107192131 to 130462130
Trading commenced on December 09, 2025
Lock-in periods extend up to June 30, 2027 for certain shares
👀 What to Watch
Investors should review the lock-in details in Annexure I to understand any restrictions on trading these newly listed shares. Monitor the trading activity of these shares for any potential impact on the stock price.
